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A B S T R A C T
Introduction: Children may be unable or unwilling to swallow medicines. In order to avoid or
accommodate any such problems, parents may decide to administer medicines other than intended. The
aim of this study was to investigate how parents administered four oral placebo formulations to infants
and preschool children and how the applied methods correlated with child acceptability.
Methods: Parents were asked to administer a 4 mm mini-tablet, powder, suspension and syrup to their
child twice on one day and to report the child characteristics and administration details in a participant
diary.
Results: A 151 children were included. The tablet, syrup and suspension were mostly given on their own,
whereas the powder was commonly given with food or drink. Generally, the higher the child acceptability
(VAS-score) of the ﬁrst administration of a speciﬁc formulation, the less frequently its method of
administration was changed. A change in the method of administration of the same formulation
involving (a larger quantity of) food or drink generally resulted in a higher VAS-score.
Conclusions: The joint administration of medicines with food or drink is an effective strategy to ensure
swallowing. This study supports earlier ﬁndings that 4 mm mini-tablets are a suitable dosage form from
infant age.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In young children, the correct use of medicines poses speciﬁc
challenges to parents, caregivers and health care professionals that
are usually not encountered in adults (Matsui, 2007; Breitkreutz
and Boos, 2007; Polaha et al., 2008; Bain-Brickley et al., 2011; Terry
and Sinclair, 2012). For example, the medicine may not be
commercially available in the required strength (a 2 mg tablet
needs breaking or splitting to administer a 1 mg dose), the
medicine may not be available in a dosage form that the child is
able to take (babies cannot swallow large tablets), or the medicine
may not be available in a dosage form that the child is willing to* Corresponding author at: Medicines Evaluation Board in The Netherlands,
Department of Chemical Pharmaceutical Assessment, P.O. Box 8275, 3503 RG,
Utrecht, The Netherlands.
E-mail address: da.v.riet@cbg-meb.nl (D.A. van Riet-Nales).
1 Until June 2011 this department belonged to the National Institute for Public
Health and the Environment (RIVM)
http://dx.doi.org/10.1016/j.ijpharm.2015.06.047
0378-5173/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article untake (bad taste; adequate taste, but child does not like it;
recalcitrance) (Balakrishnan et al., 2007; Balakrishnan et al.,
2006; van Riet-Nales et al., 2011; Walsh et al., 2014).
Clear instructions on how to overcome any administration
challenges are hardly available (Ernest et al., 2012). As a
consequence, parents, caregivers and health care professionals
may handle medicines in ways that they consider best in a
particular situation, such as breaking, crumbling or crushing
tablets, mixing medicines with food or drink, or even refraining
from administering them (Ernest et al., 2012; Richey et al., 2013;
Milani et al., 2010). All these strategies may reduce clinical efﬁcacy
and/or increase the risk of adverse drug reactions when the dosing
accuracy, chemical stability, physical stability and/or bio-availabil-
ity of a formulation is affected (Choonara and Conroy, 2002;
Cuzzolin et al., 2006; Bellis et al., 2013).
In a previous study amongst infants and preschool children in
the domiciliary setting, we showed that the child and parent
acceptability were related to the type of an oral formulation, e.g.,
tablet or syrup, and that there is no reason to question theder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Riet-Nales et al., 2013). In this study, we investigated how parents
administer different types of oral formulations to infants and
preschool children at home, and whether the applied methods
correlate with child acceptability.
2. Materials and methods
2.1. Study design and setting
The analysis is based on data collected for a randomized cross-
over trial (RCT) that investigated the child and parent acceptability
of four oral placebo formulations in infants and preschool children
in the Netherlands and that has been described in detail elsewhere
(van Riet-Nales et al., 2013). The current analysis had already been
planned in the RCT protocol (ISRCTN63138435). In brief, 151
children were recruited through six preschool preventive health
care clinics in the Netherlands. Children were eligible for inclusion
if they were 1–4 years old and excluded if they suffered from a
condition that might negatively affect swallowability. They were
also excluded if they were (potentially) hypersensitive to any of the
excipients in the formulations.
Parents were instructed verbally and in writing to offer the
formulations to their child at home in the same way as they would
administer a prescribed medicine, but without any mental or
physical pressure. Each formulation had to be administered twice
on the same day and in a randomized order for the type of
formulation i.e., at eight occasions. Parents did not receive any
additional instruction on how to administer the formulations to
their child other than that the suspension had to be shaken prior to
use. This implies that tablet chewing was neither recommended
nor forbidden. The placebo character of the formulations was
known to the parents and, when appropriate, explained to the
child.
Acknowledging that participant adherence to the study
protocol and the correct recording of data cannot be fully
controlled in a domiciliary setting, particular attention was paid
to assuring that parents well understood the aim of the study; why
it was so important to behave similarly as if they needed to
administer a prescribed medicine with the only instruction “twice
daily”; and how the diary had to be ﬁlled in.
The four tested formulations (Fig. 1) were aimed at a neutral
taste by choosing a composition that was simple, applyingFig. 1. Oral placebo formulations in this study (4-mm tablet, powder, suspension,
syrup).excipients that are commonly used in (pharmacy compounded)
paediatric medicines and by omitting the use of ﬂavouring
substances and/or taste maskers:
 White to off-white, round, biconvex, uncoated tablet (also
referred to as mini-tablet), diameter 4 mm, height 3.05/2.50 mm
(top/edge), weight 43.0 mg. Composition: lactose monohydrate
34.69 mg; maydis amylum 6.46 mg; maydis amylum pregeliﬁ-
catum 1.42 mg; magnesium stearate 0.43 mg. The tablets were
packed in a PVC/Al blister.
 White, freely ﬂowing powder (granules), 250 mg per single dose.
The composition of the powder is proportionally identical to the
tablet with exception of the lack of magnesium stearate i.e.,
lactose monohydrate 203.7 mg; maydis amylum 38.0 mg;
maydis amylum pregeliﬁcatum 8.3 mg. The powder was packed
in a white sachet.
 White, opaque suspension; 2.5 ml per single dose. Composition:
methylparahydroxybenzoate 46.0 mg; aluminium magnesium
silicate 484.4 mg; carboxymethylcellulose 484.5 mg; citric acid
36.3 mg; sucrose 12.74 g; puriﬁed water 37.95 g; microcrystalline
cellulosis 2.50 g; puriﬁed water ad 50 ml. The suspension was
packed in a 50-ml brown glass container with white, syringe
adapter that could be connected to a 3-ml oral syringe.
 Clear, colourless syrup (solution); 2.5 ml per single dose.
Composition: methylparahydroxybenzoate 63.1 mg; propylpar-
ahydroxybenzoate 10.0 mg; citric acid monohydrate 37.5 mg;
saccharose 8.28 g; puriﬁed water ad 50 ml. The container closure
system and dosing device were identical to those used for the
suspension.
In order to avoid that parents would accidentally mix up the
suspension and syrup upon administration and/or data recording,
a red sticker was put on the cap of the suspension and a blue sticker
on the cap of the syrup. In the participant diary, the colour of the
sticker was repeated where appropriate. Also, parents were asked
to conﬁrm that they had used “the bottle with the correct colour of
the sticker” when starting the data recording of the suspension and
syrup.
2.2. Data collection
After each of the eight administrations, parents were asked to
provide information in a participant diary on: (1) whether the
formulation was offered to the child (yes, no) and, if not, why not;
(2) by whom the formulation was offered to the child (father,
mother, other); (3) whether the tablets were broken, crumbled or
crushed prior to administration; (4) whether the oral liquids
(suspension and syrup) were administered with the co-dispensed
oral syringe or otherwise; (5) whether the formulations were given
with food or drink and, if so, which type and quantity; (6) child
acceptability according to the parents’ observation as measured on
a 0–10 cm Visual Analogue Scale (VAS-score); (7) child acceptabil-
ity as measured by the result of each intake (fully swallowed, partly
swallowed; not swallowed); (8) other aspects of the administra-
tion (optional).
The majority of the information could be provided by ticking
box outcomes that were based on the results of an earlier
questionnaire study in the Netherlands on the problems
encountered by parents when administering medicines to
children (van Riet-Nales et al., 2010). Where appropriate,
parents were given the possibility to provide an open answer.
Other questions in the participant diary related to child and
family characteristics and child and parent formulation
preferences.
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The method of administration was classiﬁed as “directly” when
a formulation was given on its own, as “co-administered” when a
formulation was given with a small quantity of food or drink (one
bite/sip), and as “mixed” when a formulation was given with a
larger quantity of food or drink (several bites/sips). For the purpose
of testing associations involving these three methods of adminis-
tration, we have taken the ordinal character of this variable into
account by labelling its three levels as 1, 2 and 3.
The association between the method of administration and the
type of formulation, which is naturally expected to exist, was
checked ﬁrst. Then the following associations were investigated
separately for each type of formulation: (1) association between
the method of administration and the VAS-score; (2) association
between the method of administration and the result of the intake;
(3) association between the ﬁrst VAS-score (the score at the ﬁrst
administration) and the change in the method of administration
(from the ﬁrst to the second administration); (4) association
between the change in the method of administration (from the ﬁrst
to the second administration) and the change in VAS-scores.
The analysis took account of the small effect that was observed
for the order in which the four formulations were administered to a
child (van Riet-Nales et al., 2013). The testing of associations was
based on a permutation version of Spearman’s test for indepen-
dence. In this test the null distribution is approximated by
randomly permuting the data separately within the 24 groups
pertaining to the different orders of administration of the four
formulations.
The data were analysed by Excel 2007 (Microsoft Corporation,
Redmond, Washington), SPSS version 17.0 (IBM) and R (version
2.13, R development team). Spearman’s test was conducted with
the R package coin (Hothorn et al., 2006).
3. Results
A hundred and ﬁfty-one children were included, 72 (48%) of
which were boys and 79 (52%) girls. Fifty-ﬁve (36%) children were
12–23 months old; 32 (21%) 24–35 months, and 64 (42%) 36–51
months old. For the ﬁrst/second administration, the tablet was
offered to the child on all occasions, the powder on all but two/ﬁveFig. 2. Illustration type of formulation and method of administraoccasions; the suspension on all but one/ﬁve occasions and the
syrup on all but four/ﬁve occasions. One thousand and six (84.8%)
of all administrations were carried out by the mother, 173 (14.6%)
by the father, and 7 (0.6%) by another caregiver.
The main reason (n = 17, 77%) for not offering a formulation to a
child was either that the parent considered that the child would
refuse it anyway or that the child actually said so to his/her parent.
On 14 (4.6%) occasions the tablet was broken, crumbled or crushed
prior to administration, in one occasion at the ﬁrst administration
only (age child 16 months), in three occasions at the second
administration only (age children 19, 31, 45 months) and in ﬁve
occasions at both administrations (age children 12, 20, 33, 31, 48
months). On 58 (20%) occasions the suspension was emptied into a
spoon prior to administration and so was the syrup on 57 (19%)
occasions.
The tablet, suspension and syrup were given mainly directly
(tablet n = 249, 82%; suspension n = 266, 90%; syrup n = 271, 92%).
However, the powder was mainly given with food or drink (co-
administered: n = 119, 40%; mixed n = 71, 24%). On two occasions
(ﬁrst and second administration of the powder for the same child)
the method of administration was unknown.
As expected, the method of administration depends signiﬁ-
cantly on the type of formulation (p-value <0.001 from a chi-
square test). An illustration of this dependence for children of
different ages is provided in Fig. 2 (children of 48–51 months are
presented as 3 years). The foodstuffs most commonly used for co-
administration or mixing were vanilla pudding, quark, yoghurt,
porridge and fruit sauce.
An evaluation of the acceptability of the formulations (overall
child and parent VAS-score, result of the intake) has already been
published elsewhere (van Riet-Nales et al., 2013). For formulations
fully swallowed, an illustration of the association between the
method of administration and the (child) VAS-score is given in
Fig. 3 for each type of formulation. The differences suggested by
Fig. 3 appear to be signiﬁcant for the tablet and suspension even
when ignoring the result of the intake i.e. when, considering all
administrations (p-values <0.001 and 0.0146), but not for the
powder (p = 0.701) nor the syrup (p = 0.495).
Considering all occasions where a particular formulation was
given to a child (tablet n = 302; powder n = 295; suspension n = 296,
syrup n = 293), a VAS-score of 8–10 was obtained for the tablet ontion for children of different ages (n = 1206 administrations).
Fig. 3. Illustration association method of administration and child VAS-score
(formulations fully swallowed only).
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administered and on 8 (3%) when mixed; for the suspension, on
196 (66%) occasions when given directly, on 5 (2%) when co-
administered, on 12 (4%) when mixed; for the syrup, on 201 (69%)
occasions when given directly, on 9 (3%) when co-administered
and on 10 (3%) when mixed. For the powder, a VAS score of 8–10
was almost as often achieved when given directly (n = 74, 25%) as
when co-administered (n = 78, 26%) or mixed (n = 59, 20%).
As expected and illustrated in Fig. 4, the VAS-score is in good
agreement with the result of the intake. However, it is clear that
good acceptability did not guarantee full swallowing on all
occasions, e.g., because parents stated that the formulation got
spoiled during the intake or that it dropped out of the child’s
mouth. Similarly, bad acceptability did not always imply lack ofFig. 4. Illustration agreement result of the intake and child VAS-score.swallowing, as parents indicated that the child only showed its
disgust afterwards.
When given directly, the tablet was fully swallowed on 241
occasions (equalling 97% of all direct tablet administrations), the
powder on 87 (85%), the suspension on 241 (91%) and the syrup on
234 (86%). When co-administered, the tablet was fully swallowed
on 43 (95%) occasions and the powder on 95 (80%). Finally when
mixed, the tablet was fully swallowed on 8 occasions (100%) and
the powder on 60 (84%). Considering the youngest children only
(12–23 months), the tablet was given directly and fully swallowed
by 82 (75%) of these children.
Considering only occasions on which the formulations were
given directly and fully swallowed, good acceptability (i.e., a VAS-
score 8–10) was obtained for the tablet on 221 occasions (73%), for
the powder on 70 (24%), for the suspension on 195 (66%), and for
the syrup on 199 (68%). The association between the method of
administration and the result of the intake was found to be
signiﬁcant for the suspension (p < 0.001), but not for the tablet
(p = 0.271), the powder (p = 0.383) and the syrup (p = 0.105). There
was good evidence that the higher the VAS-score of the ﬁrst
administration of a formulation to a child is, the less frequently the
method of administration of this formulation is changed from the
ﬁrst to the second administration (tablet p = 0.001, powder
p = 0.367, suspension p = 0.031, syrup p = 0.046). For example, when
the VAS-score in the ﬁrst administration was 8–10, the method of
administration was not changed in most cases (tablet 94%, powder
82%, suspension 98%, syrup 96%).
A change in the method from the ﬁrst to the second
administration is denoted as “more complex” when it involved a
larger quantity of food or drink (going from “directly” to “co-
administered”, from “directly” to “mixed” or from “co-adminis-
tered” to “mixed”). Conversely, it is denoted as “less complex”
when it involved a smaller quantity of food or drink (going from
“mixed” to “co-administered”, from “mixed” to “directly” or from
“co-administered” to “directly”). Except for the suspension, strong
evidence was found for an association between changes in the
method of administration and changes in the VAS-score. The
results indicated that a change into a more complex method of
administration overall resulted in higher VAS-scores (tablet
p = 0.005, powder p < 0.001, suspension p = 0.168, syrup p = 0.001).
In Fig. 5, the changes in the method of administration and the
resulting changes in VAS-scores are illustrated in three groups that
are indicative of the acceptability of the ﬁrst administration. The
groups were based on the results displayed in Fig. 3 i.e. bad
acceptability VAS-score 0–2; moderate acceptability VAS-score
3–7 and good acceptability VAS-score 8–10. As expected, the
method of administration changed more frequently into a more
complex method when the VAS-score of the ﬁrst administration
was low (VAS score 0–2; n = 11/45; 24%) than when it was higher
(VAS score 3–10; n = 33/552; 6%).
4. Discussion
This study showed that oral placebo formulations in the form of
a 4 mm tablet, a suspension and a syrup were mostly administered
to infants and preschool children on their own and that the placebo
powder was mostly given with food or drink. As the joint
administration of the formulations with food or drink was neither
recommended on the product label nor in the participant
information, from a regulatory perspective this implies that the
formulations had to be given on their own. Thus the result of this
study indicate that the tablet, suspension and syrup were given as
intended, and the powder was not.
As expected, the method of administration was clearly
associated with the type of formulation. For the tablet and
suspension, the method also appears to be associated with child
VAS = 0 to 2 VAS = 3 to 7 VAS = 8 to 10 Less complex
techniq ue
More complex
techniq ue
2nd
administration
refused
Same techniq ue
Fig. 5. Association child VAS-score ﬁrst administration of a formulation and changes in method of administration from ﬁrst to second administration.
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the VAS-score, and for the suspension with the result of the intake.
Parents were more likely to administer a formulation with (a larger
quantity of) food or drink when the VAS-score of the earlier
administration of the same formulation was low than when it was
high(er). Changes in the method from the ﬁrst to the second
administration of the same formulation generally resulted in
higher VAS-scores.
The limited availability and age-appropriateness of medicines
for children has resulted in a globally emerging effort towards an
improvement of paediatric medicines (van Riet-Nales et al., 2011;
Ranmal and Tuleu, 2013; Choonara, 2008). As suggested by
Kozarewicz (2014), this requires the collection of pre-marketing
data on the acceptability of medicines by children. However, a
suitable methodology for collecting and making sense of such data
is yet to be developed. Therefore, the selection of the test methods
and the proposals for data assessment are currently left to
researchers (Ranmal and Tuleu, 2013; Kozarewicz, 2014).
According to Ranmal and Tuleu (2013), researchers should,
amongst other things, consider the variability in child acceptability
in typical and atypical populations, acknowledge that acceptability
testing based on small samples may lead to inconsistent and
limited ﬁndings, and realise that parents may be more likely to
participate in a study when they feel positive about the
formulation being investigated. Kozarewicz (2014) and Ranmal
and Tuleu (2013) remarks were considered in the patient
recruitment and design of our RCT.
In order to mimic the administration of paediatric medicines by
parents to the best extent, the study was conducted in the
domiciliary setting and tablet chewing was neither recommended
nor forbidden. The latter approach is consistent with current
regulatory provisions indicating that “immediate release tablets
are normally intended to be swallowed intact, but unless
otherwise indicated in the SmPC and PIL, they may also be
chewed” (European Medicines Agency Committee for Medicinal
Products for Human Use (CHMP) and Paediatric Committee (PRAC),
2013).
Generally, parents and caregivers will have less experience in
administering medicines to children than nurses working on
paediatric wards. However, Akram and Mullen (2012) indicated
that parents often advised staff as to whether their child’s
medication needed to be co-administered or mixed with food or
drink or otherwise modiﬁed in order to enable swallowing. Also
Alsulami et al. (2012) indicated that the most frequent type of
deviations from hospital policy on the administration of medicines
to children was that the formulation was given by the parents
without the nurse being present. Thus the ﬁndings of our study will
also be of relevance to children who are hospitalized.
The variability in child characteristics was addressed by
focusing on generally healthy domiciliary children who did not
have any difﬁculties swallowing food or drink. In addition, thevariability in parents' attitudes to study participation was
acknowledged by two means. First, recruitment was conducted
through national preventive health care clinics in view of the high
response to invitation of the overall population of parents
(Rijksinstituut voor Volksgezondheid en Milieu, 2011). Second,
the likelihood that parents were more willing to participate in a
study when they were positive to a certain formulation was
avoided by studying four types of oral placebo formulations and
allowing parents not to administer a particular formulation if they
rather did not like to do so.
Following discussions with Dutch health care professionals and
taking data from the palatability and pain literature into account,
we measured child acceptability by two instruments, namely the
child VAS-score and the result of the intake. For the VAS-scale, the
commonly applied facial expressions below the line indicating
“like” and “dislike” were replaced with words relating as to
whether the child considered the intake unpleasant or not at all.
This is because we consider there is no need that children actually
“like” taking medication.
The increasing global focus on better medicines for children has
also resulted in an increased focus on small i.e. mini-tablets.
Whereas our study related to 4 mm tablets, other authors tend to
study smaller sizes, e.g., 3-mm by Thomson et al. (2009) 2-
Klingmann et al. (2013). Such smaller tablet sizes entail an
increased need to swallow several mini-tablets to arrive at the
recommended dose as the maximum amount of active substance
per mini-tablet is limited. However, at the same time this would
allow better dosing ﬂexibility. In any case it should be acknowl-
edged that a larger number of mini-tablets may make the
administration more “powder like”. Or alternatively more “sus-
pension like” when applying a novel approach by which the
addition of some water to several mini-tablets results in a semi-
solid mass. In both cases, child acceptability may change in
comparison to the administration of a single mini-tablet. Recently,
Kluk et al. (2015) have studied the swallowability of ﬁve to ten 2-
mm and 3-mm tablets that were administered on a spoon with
fruit gel to children aged two to three years old in an institutional
setting. The results showed that children could swallow these
numbers of mini-tablets safely (Kluk et al., 2015). Nevertheless, the
acceptability of several mini-tablets of different sizes, in children of
different ages and in different settings remains subject to further
investigations.
Current studies on medication adherence focus mainly on the
ability of parents to calculate and measure the recommended
dose, on the eventual relationship between health literacy and
deviations from the written user instruction, and on the
effectiveness of verbal, written or pictogram interventions
designed to encourage adequate administration practices (Ander-
son et al., 2013; Bertsche et al., 2010; Lokker et al., 2009). Studies
on the associations that were investigated in this study are more
scarce. Akram and Mullen (2015) investigated the prevalence and
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by nurses working in a national health service, and (Richey et al.
(2013) studied which dosage forms and drugs were routinely
modiﬁed in paediatric clinical practice. Both studies were
conducted in the United Kingdom amongst nurses, in relation
to any type of prescribed medicine and to a wide variety of
children. These studies as well as our study share the conclusion
that medicines may be given with food or drink or otherwise be
modiﬁed to guarantee adequate child acceptability and/or
medication intake.
Akram and Mullen (2012) indicated that nurses rather added
the medications to the foodstuff instead of adding the foodstuff to
the medicines. This aspect was not investigated in our study as we
considered that it is the quantity of the food or drink that is being
used that is most important. First, it is likely that the contact time
and/or area will be smaller when a formulation is given with a
small quantity of food or drink (one bite/sip) than when it is mixed
with a larger quantity (several bites/sips). If so, this may reduce the
risk for and/or impact of any chemical or physical interactions on
the bioavailability and stability of the formulation, and therewith
on its clinical efﬁcacy and risk for adverse drug reactions. Second,
children may not be willing to swallow larger quantities of
medicated food or drink fully. Depending on the criticality of the
disease and the type of medicine, this may put the child at an
immediate risk. Third, verbal reports from Dutch health care
professionals stated that feeding problems may be due to negative
experiences involving medicated food. Consequently, they argued
that it is important that medicines be given only with a small
quantity of food or drink, and that the remaining quantity of the
non-medicated food or drink should be given immediately after.
However, this opinion was not conﬁrmed by evidence in the public
domain (Lifschitz, 2001).
This study has several strengths. It is, to the best of our
knowledge, the ﬁrst study comparing the method of administra-
tion and child acceptability of different types of oral formulations
in infants and preschool children in the domiciliary setting. This
setting was selected because oral formulations are frequently
taken by children who are not and also have not been hospitalized,
whereas hospitalized children may need to take oral formulations
at home for long periods of time after discharge. The choice for the
domiciliary setting also implied that the study outcomes take
account of any impact on the method of administration and child
acceptability caused by child–parent relations, child–sibling
relations, parents’ understanding of the user instruction and the
absence of a supervising health care professional (Thomson et al.,
2009; Klingmann et al., 2013).
This study has some weaknesses also. First, the participant
diary included tick-box outcomes that were supplemented with
the possibility to provide an open answer. Although unlikely
because of the detailed verbal instructions to data in the
participant diary, it cannot be excluded that the pre-printed
administration possibilities might have inﬂuenced the method
actually applied by the parents. Second, the sample size was based
on the primary aim of the former RCT rather than this analysis
itself. Third, the taste of the two oral solid formulations was
identical as they were manufactured from essentially the same
blend. However, the taste of the two oral liquid formulations
differed due to the intrinsic nature of their dosage form. Although
the taste of all four formulations was aimed at neutral, it cannot be
excluded that any differences in child acceptability or the method
of administration were due to taste aspects rather than the type of
dosage form itself. Fourth, the current analysis did not consider the
22 occasions where the syrup, suspension and powder were not
offered to the child for anticipated child refusal i.e., when the child
acceptability was expected to be bad. This weakness must be
considered when disputing the suitability of small tablets as analternative dosage form to a powder, suspension or syrup for the
reason that they were broken, crumbled or crushed in 14 occasions.
In addition, the results of this study should be considered
realizing that the study was limited to four types of oral
formulations with deﬁned characteristics and to Dutch parents
and children living in a small region of the Netherlands (“Rivieren-
land”). Finally, this study showed that parents may empty the dose
from the oral syringe onto a household spoon prior to administra-
tion. We consider that this handling can be accepted without any
further justiﬁcation as the risk for additional loss of dose is
negligible.
The method of administration was associated with the type of
formulation. However, it was only associated with the VAS-score
and the result of the intake in the case of the suspension. Overall,
this suggests that it is mainly the type of formulation that made
parents decide to administer a formulation with food or drink.
However, when parents observed that the VAS-score of the ﬁrst
administration was low, they frequently chose to administer the
formulation with (a larger quantity of) food or drink. This approach
turned out to be effective i.e., to improve child acceptability.
Considering clinical practice and the fact that pharmaceutical
companies are generally reluctant to conduct compatability
studies between a formulation and a speciﬁc type of food or
drink, regulators are considering precautionary warnings in the
user instruction stating that the formulations should not be taken
with food or drink unless compatibility had been demonstrated.
Although these warnings are intended to protect the health of the
child by avoiding any impact of food or drink on the stability and
bio-availability of the formulation, they may in fact put the child at
risk if the warning withholds the child from taking its medicine.
Since our study points towards the latter possibility, it is
recommended that regulators carefully consider the risk for
reduced adherence rates when implementing warnings. This may
be especially relevant for powders, which are commonly given
with food or drink. Actually, we consider that it is not at all in the
interest of children to implement warnings that are solely based on
the absence of data supporting adequate compatibility, and
certainly not when an interaction is not to be expected on
scientiﬁc grounds.
The optional remarks written by the parents on the participant
diary indicate that the type of dosing device may have had an effect
on child acceptability. Some parents stated that their child “wanted
more” of the suspension or syrup because the child knew it would
be allowed to play with the empty syringe when both doses were
taken, whereas other parents indicated that they emptied the oral
suspension or syrup into a spoon because the child was afraid of
the syringe. Thus, the design and child acceptability of syringes for
oral use should be further investigated.
5. Conclusions
The 4-mm tablet, suspension and syrup were largely adminis-
tered without any food or drink and without breaking, crumbling
or crushing tablets. This shows that parents who master the Dutch
language are generally handling these types of formulations in a
manner that is consistent with the regulatory perception that users
may only handle medicines in a manner that is recommended in
the authorised product/user information (package label, patient
information leaﬂet, Summary of Product Characteristics)
The powder was commonly given with food or drink, yet this
handling was not recommended on the package label and also not
in the participant information. This underpins the need for better
instructions in the user information on the method of administer-
ing this dosage form.
Formulations that were administered with food or drink were
generally so for good reason i.e., to improve child acceptability.
D.A. van Riet-Nales et al. / International Journal of Pharmaceutics 491 (2015) 261–267 267Consequently, any warnings in the user formation on the mixing of
medicines with food or drink must be carefully balanced against
the risk of reduced child acceptability and reduced adherence
rates, especially when there is no clear evidence of a medicine-food
interaction that is likely to result in a clinically relevant effect.
Our results indicate that the overall acceptability of a small i.e.
mini-tablet) versus a powder, suspension or syrup formulation is
unlikely to alter due to crumbling, crushing or giving the tablet
with food or drink. Therefore, this study further support our earlier
conclusion that there is no reason to dispute the acceptability of
small tablets in young children (van Riet-Nales et al., 2013).
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